Artiva Biotherapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2023 to Q4 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Artiva Biotherapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2023 to Q4 2024.
  • Artiva Biotherapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending December 31, 2024 was -$16.1M, a 34.1% decline year-over-year.
  • Artiva Biotherapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending December 31, 2024 was -$65.4M, a 128% decline year-over-year.
  • Artiva Biotherapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2024 was -$65.4M, a 128% decline from 2023.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q4 2024 -$65.4M -$16.1M -$4.1M -34.1% Oct 1, 2024 Dec 31, 2024 10-K 2025-03-24
Q3 2024 -$61.3M -$17.5M -$28.8M -255% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-12
Q2 2024 -$32.5M -$17.8M -$6.56M -58.1% Apr 1, 2024 Jun 30, 2024 10-Q 2024-11-12
Q1 2024 -$26M -$14M +$2.75M +16.5% Jan 1, 2024 Mar 31, 2024 10-Q 2024-11-12
Q4 2023 -$28.7M -$12M Oct 1, 2023 Dec 31, 2023 10-K 2025-03-24
Q3 2023 $11.3M Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-12
Q2 2023 -$11.3M Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-12
Q1 2023 -$16.7M Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.